Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#41
JOURNAL ARTICLE
Shengmin Zhang, Pieter De Frenne, Dries Landuyt, Kris Verheyen
Throughfall deposition is an important pathway via which particles, aerosols and gases can move from the atmosphere to the forest floor, which can greatly impact forest biodiversity and functioning. Although throughfall deposition biochemistry has been well studied in forest ecosystems, less is known about how throughfall deposition is modified by tree species diversity. To disentangle the effects of tree species identity and diversity on throughfall deposition, we installed rain gauges in a 10-year-old tree diversity experiment...
June 23, 2022: Science of the Total Environment
#42
JOURNAL ARTICLE
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen-Chieh Chuang, Julie Lin, Wen-Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V Kowdley, Aliya Gulamhusein, Christopher L Bowlus, Ryan S Huss, Robert P Myers, Chuhan Chung, Andrew N Billin
BACKGROUND AND AIMS: Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood. Our aim was to evaluate serum IL-31 as a putative biomarker of pruritus in clinical trials of an farnesoid X receptor (FXR) agonist, cilofexor, in patients with NASH, primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC). APPROACH AND RESULTS: Serum IL-31 was measured in clinical studies of cilofexor in NASH, PSC, and PBC...
June 10, 2022: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#43
JOURNAL ARTICLE
Isabelle Dehaene, Tessa Van Steenstraeten, Kris De Coen, Stefanie De Buyser, Johan Decruyenaere, Koenraad Smets, Kristien Roelens
UNLABELLED: To objective of this study was to compare neonatal magnesemia in the first 15 days of neonatal life between three groups: a control group not exposed to MgSO4 , a neuroprotection group, and an eclampsia prevention group, and to explore its associations with child outcomes. A retrospective single-centre cohort study was performed in a tertiary care setting. Infants admitted at the neonatal intensive care unit born between 24 and 32 weeks' gestation, regardless of etiology of preterm birth, were included...
August 2022: European Journal of Pediatrics
#44
RANDOMIZED CONTROLLED TRIAL
Jicheng Lv, Muh Geot Wong, Michelle A Hladunewich, Vivekanand Jha, Lai Seong Hooi, Helen Monaghan, Minghui Zhao, Sean Barbour, Meg J Jardine, Heather N Reich, Daniel Cattran, Richard Glassock, Adeera Levin, David C Wheeler, Mark Woodward, Laurent Billot, Sandrine Stepien, Kris Rogers, Tak Mao Chan, Zhi-Hong Liu, David W Johnson, Alan Cass, John Feehally, Jürgen Floege, Giuseppe Remuzzi, Yangfeng Wu, Rajiv Agarwal, Hong Zhang, Vlado Perkovic
IMPORTANCE: The effect of glucocorticoids on major kidney outcomes and adverse events in IgA nephropathy has been uncertain. OBJECTIVE: To evaluate the efficacy and adverse effects of methylprednisolone in patients with IgA nephropathy at high risk of kidney function decline. DESIGN, SETTING, AND PARTICIPANTS: An international, multicenter, double-blind, randomized clinical trial that enrolled 503 participants with IgA nephropathy, proteinuria greater than or equal to 1 g per day, and estimated glomerular filtration rate (eGFR) of 20 to 120 mL/min/1...
May 17, 2022: JAMA
#45
JOURNAL ARTICLE
Chesney K Richter, Ann C Skulas-Ray, Trent L Gaugler, Stacey Meily, Kristina S Petersen, Penny M Kris-Etherton
OBJECTIVE: Recommended dietary patterns improve cardiovascular disease (CVD) risk factors such as blood pressure and LDL-C, as well as emerging markers that confer residual risk. Strawberry consumption has been shown to improve CVD risk factors, but further research is needed to better understand these effects using a dose-response model that evaluates a standard serving and a higher (but still achievable) dose. METHODS: A randomized, placebo-controlled, double-blinded crossover trial was conducted in middle-aged adults with overweight or obesity ( n = 40; mean BMI = 29...
February 23, 2022: J Am Nutr Assoc
#46
RANDOMIZED CONTROLLED TRIAL
Jose F Varona, Pedro Landete, Jose A Lopez-Martin, Vicente Estrada, Roger Paredes, Pablo Guisado-Vasco, Lucia Fernandez de Orueta, Miguel Torralba, Jesus Fortun, Roberto Vates, Jose Barberan, Bonaventura Clotet, Julio Ancochea, Daniel Carnevali, Noemi Cabello, Lourdes Porras, Paloma Gijon, Alfonso Monereo, Daniel Abad, Sonia Zuñiga, Isabel Sola, Jordi Rodon, Julia Vergara-Alert, Nuria Izquierdo-Useros, Salvador Fudio, Maria Jose Pontes, Beatriz de Rivas, Patricia Giron de Velasco, Antonio Nieto, Javier Gomez, Pablo Aviles, Rubin Lubomirov, Alvaro Belgrano, Belen Sopesen, Kris M White, Romel Rosales, Soner Yildiz, Ann-Kathrin Reuschl, Lucy G Thorne, Clare Jolly, Greg J Towers, Lorena Zuliani-Alvarez, Mehdi Bouhaddou, Kirsten Obernier, Briana L McGovern, M Luis Rodriguez, Luis Enjuanes, Jose M Fernandez-Sousa, Nevan J Krogan, Jose M Jimeno, Adolfo Garcia-Sastre
Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies. Simultaneously, in this randomized, parallel, open-label, proof-of-concept study (NCT04382066) conducted in 10 Spanish hospitals between May and November 2020, 46 adult hospitalized patients with confirmed SARS-CoV-2 infection received either 1...
April 2022: Life Science Alliance
#47
JOURNAL ARTICLE
Kathryn C Arbour, Eusebio Manchado, Matthew J Bott, Linda Ahn, Yosef Tobi, Andy Ai Ni, Helena A Yu, Alyssa Shannon, Marc Ladanyi, Victoria Perron, Michelle S Ginsberg, Amanda Johnson, Andrei Holodny, Mark G Kris, Charles M Rudin, Piro Lito, Neal Rosen, Scott Lowe, Gregory J Riely
Introduction: Somatic KRAS mutations occur in 25% of patients with NSCLC. Treatment with MEK inhibitor monotherapy has not been successful in clinical trials to date. Compensatory activation of FGFR1 was identified as a mechanism of trametinib resistance in KRAS-mutant NSCLC, and combination therapy with trametinib and ponatinib was synergistic in in vitro and in vivo models. This study sought to evaluate this drug combination in patients with KRAS-mutant NSCLC. Methods: A phase 1 dose escalation study of trametinib and ponatinib was conducted in patients with advanced NSCLC with KRAS mutations...
January 2022: JTO clinical and research reports
#48
Daan Zillen, Kris L L Movig, Gert Kant, Joost B Masselink, Paola Mian
BACKGROUND: Acetaminophen hepatotoxicity is thought to be primarily caused by formation of the specific reactive metabolite N-acetyl-para-benzo-quinone imine (NAPQI). Malnourished individuals are at increased risk of acetaminophen-related hepatotoxicity. We report a case of low acetaminophen clearance in a severely underweight young woman, and elaborate on the possible effects of malnutrition on the total clearance of acetaminophen as well as on the separate contributions of the different metabolic pathways...
November 2021: Clinical Case Reports
#49
JOURNAL ARTICLE
Anil Babu Payedimarri, Matteo Ratti, Riccardo Rescinito, Alessandra Vasile, Deborah Seys, Hervé Dumas, Kris Vanhaecht, Massimiliano Panella
Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations. The quality of the care received by patients affected with MG could benefit from the use of CP. We conducted a study aimed to define an inclusive, comprehensive, and multidisciplinary CP for the diagnosis, treatment, and care of MG...
November 4, 2021: International Journal of Environmental Research and Public Health
#50
JOURNAL ARTICLE
Albert C Yeh, Paul V O'Donnell, Gary Schoch, Paul J Martin, Chris McFarland, Jeannine S McCune, Jason P Cooper, Kris Doney, Mary E D Flowers, Mohamed L Sorror, Frederick R Appelbaum, Barry E Storer, Ted Gooley, H Joachim Deeg
We evaluated long-term outcome in 40 patients with MDS or AML, transplanted from related or unrelated donors following conditioning with targeted busulfan (Bu, over 4 days), fludarabine (Flu, 120 [n = 23] or 250 [n = 17] mg/m2 ) and thymoglobulin (THY). Compared to 95 patients conditioned with Bu/Cyclophosphamide (Cy) without THY, BuFluTHY-conditioned patients had lower rates of chronic graft-vs.-host disease (GVHD). Adjusted hazard ratios (HR) for BuFlu(120)THY and BuFlu(250)THY-conditioned patients were 1...
November 5, 2021: Bone Marrow Transplantation
#51
JOURNAL ARTICLE
Vlad Ratziu, Mary E Rinella, Brent A Neuschwander-Tetri, Eric Lawitz, Douglas Denham, Zeid Kayali, Aasim Sheikh, Kris V Kowdley, Taddese Desta, Magdy Elkhashab, Jeffery DeGrauw, Bryan Goodwin, Alaa Ahmad, Nathalie Adda
BACKGROUND & AIMS: EDP-305 is an oral farnesoid X receptor (FXR) agonist under development for the treatment of non-alcoholic steatohepatitis (NASH). Herein, we aimed to assess the efficacy, safety and tolerability of EDP-305 in patients with fibrotic NASH. METHODS: In this double-blind phase II study, patients with fibrotic NASH (without cirrhosis), diagnosed by historical biopsy or phenotypically, were randomized to EDP-305 1 mg, EDP-305 2.5 mg, or placebo, for 12 weeks...
March 2022: Journal of Hepatology
#52
JOURNAL ARTICLE
Martin Gutierrez, Robin Guo, Giuseppe Giaccone, Stephen V Liu, Zhonglin Hao, Christie Hilton, James M Hinson, Mark G Kris, Everardus Otto Orlemans, Alexander Drilon
OBJECTIVES: Single-agent heat shock protein 90 (HSP90) inhibition has demonstrated activity in oncogene-driven non-small cell and small cell lung cancers. SNX-5422 is an oral HSP90 inhibitor with increased activity in vitro with the addition of carboplatin and paclitaxel. Therefore, we conducted a phase 1, open-label, multicenter study to evaluate SNX-5422, carboplatin and paclitaxel followed by SNX-5422 maintenance in patients with advanced lung cancers. MATERIALS AND METHODS: In part 1 (3 + 3 dose escalation), SNX-5422 (50/75/100-mg/m2 ) was dosed every other day (qod) for 21 days (28-day cycle) for ≤4 cycles; carboplatin (AUC 5)-paclitaxel (175 mg/m2 ) was administered once every 3 weeks for ≤6 courses...
October 8, 2021: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
#53
JOURNAL ARTICLE
Philip A Sapp, Penny M Kris-Etherton, Kristina S Petersen
BACKGROUND: The glycemic effects of peanuts are not well-studied and no trials have been conducted in adults with elevated fasting plasma glucose (FPG). Furthermore, intake of peanuts as a nighttime snack, an eating occasion affecting FPG, has not been examined. OBJECTIVE: The aim was to determine the effect of consuming 28 g/d of peanuts as a nighttime snack for 6-weeks on glycemic control and cardiovascular disease (CVD) risk factors, compared to an isocaloric lower fat, higher carbohydrate (LFHC) snack (whole grain crackers and low-fat cheese), in adults with elevated FPG...
September 25, 2021: Journal of Nutrition
#54
REVIEW
Marlies van Dijk, Kris J M Mooren, Jan-Willem K van den Berg, Wendy J C van Beurden-Moeskops, Roxane Heller-Baan, Sander M de Hosson, Wai Yee Lam-Wong, Liesbeth Peters, Karin Pool, Huib A M Kerstjens
BACKGROUND: Refractory dyspnea or breathlessness is a common symptom in patients with advanced chronic obstructive pulmonary disease (COPD), with a high negative impact on quality of life (QoL). Low dosed opioids have been investigated for refractory dyspnea in COPD and other life-limiting conditions, and some positive effects were demonstrated. However, upon first assessment of the literature, the quality of evidence in COPD seemed low or inconclusive, and focused mainly on morphine which may have more side effects than other opioids such as fentanyl...
September 10, 2021: BMC Pulmonary Medicine
#55
RANDOMIZED CONTROLLED TRIAL
Clara K Chow, Emily R Atkins, Graham S Hillis, Mark R Nelson, Christopher M Reid, Markus P Schlaich, Peter Hay, Kris Rogers, Laurent Billot, Michael Burke, John Chalmers, Bruce Neal, Anushka Patel, Tim Usherwood, Ruth Webster, Anthony Rodgers
BACKGROUND: Treatment inertia is a recognised barrier to blood pressure control, and simpler, more effective treatment strategies are needed. We hypothesised that a hypertension management strategy starting with a single pill containing ultra-low-dose quadruple combination therapy would be more effective than a strategy of starting with monotherapy. METHODS: QUARTET was a multicentre, double-blind, parallel-group, randomised, phase 3 trial among Australian adults (≥18 years) with hypertension, who were untreated or receiving monotherapy...
September 18, 2021: Lancet
#56
JOURNAL ARTICLE
Chantal Elise Mulkens, Marieke Staatsen, Lucie van Genugten, Barbara A M Snoeker, Kris C P Vissers, Jörgen Bruhn, Martin J L Bucx
BACKGROUND: A new potential target for multimodal pain management is the group-II metabotropic glutamate receptor subtypes, which can be activated by N-acetylcysteine. We investigated whether pre-emptive administration of N-acetylcysteine leads to a reduction in postoperative pain after laparoscopic inguinal hernia repair. METHODS: Sixty American Society of Anesthesiologists I-II patients scheduled for elective inguinal hernia repair were randomized to receive either N-acetylcysteine (150 mg/kg) or placebo intravenously 1 hour before surgery...
August 26, 2021: Regional Anesthesia and Pain Medicine
#57
JOURNAL ARTICLE
Kris T C Hede, Bjørn B Christensen, Morten L Olesen, Jesper Skovhus Thomsen, Casper B Foldager, Wei Seong Toh, Sai Kiang Lim, Martin C Lind
OBJECTIVE: This study evaluated the effects of mesenchymal stem cell-extracellular vesicles (MSC-EVs) on chondrocyte proliferation in vitro and on cartilage repair in vivo following bone marrow stimulation (BMS) of focal chondral defects of the knee. METHODS: Six adult Göttingen minipigs received 2 chondral defects in each knee. The pigs were randomized to treatment with either BMS combined with MSC-EVs or BMS combined with phosphate-buffered saline (PBS). Intraarticular injections MSC-EVs or PBS were performed immediately after closure of the surgical incisions, and at 2 and 4 weeks postoperatively...
July 26, 2021: Cartilage
#58
JOURNAL ARTICLE
Noura J Choudhury, Alex Makhnin, Yosef Y Tobi, Robert M Daly, Isabel R Preeshagul, Afsheen N Iqbal, Linda S Ahn, Sara A Hayes, Glenn Heller, Mark G Kris, Gregory J Riely, Helena A Yu
Patients with EGFR- mutant lung cancer have no approved targeted therapies after disease progression on first-line osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Preclinical studies suggest that tumors with both EGFR -sensitizing alteration and acquired second-site EGFR resistance alterations after treatment with osimertinib retain sensitivity to second-generation EGFR TKIs. We hypothesized that dacomitinib, a pan-human epidermal growth factor receptor TKI, may be effective in this setting...
2021: JCO Precision Oncology
#59
JOURNAL ARTICLE
Jia Luo, Alex Makhnin, Yosef Tobi, Linda Ahn, Sara A Hayes, Afsheen Iqbal, Kenneth Ng, Maria E Arcila, Gregory J Riely, Mark G Kris, Helena A Yu
Inhibition of the MEK/ERK pathway is critical for Bcl-2-like protein 11 (BIM)-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-induced apoptosis, and dysregulation of this pathway may be a mechanism of acquired resistance. Therefore, MEK inhibition with trametinib and an EGFR TKI may resensitize tumors with acquired resistance. Limited targeted therapies are available after progression on EGFR TKIs, and it is in this setting that we completed a phase I/II study of erlotinib and trametinib...
2021: JCO Precision Oncology
#60
RANDOMIZED CONTROLLED TRIAL
Aleksandar Videnovic, Amy W Amara, Cynthia Comella, Paula K Schweitzer, Helene Emsellem, Kris Liu, Amanda L Sterkel, Mildred D Gottwald, Joshua R Steinerman, Philip Jochelson, Katie Zomorodi, Robert A Hauser
BACKGROUND: Solriamfetol is approved (US and EU) for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. OBJECTIVES: Evaluate solriamfetol safety/efficacy for EDS in Parkinson's disease (PD). METHODS: Phase 2, double-blind, 4-week, crossover trial: adults with PD and EDS were randomized to sequence A (placebo, solriamfetol 75, 150, 300 mg/d), B (solriamfetol 75, 150, 300 mg/d, placebo), or C (placebo)...
October 2021: Movement Disorders: Official Journal of the Movement Disorder Society
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
